| Domain | Syndrome-specific established evidence | Evidence basis | Confidence/limitations |
|---|---|---|---|
| Identity | Bilateral microtia-deafness-cleft palate syndrome; MONDO:0012854; HOXA2-associated Mendelian disorder. | Disease–target aggregation identifies HOXA2 as the sole associated target (pqac-00000002). | High for MONDO identity and HOXA2 association; other identifiers should not be inferred without direct database confirmation. |
| Human evidence base | Reported in one consanguineous Iranian pedigree with four affected individuals. | Original family report and subsequent HOX-disorder review (pqac-00000000, pqac-00000001). | Very limited: four relatives from one family; percentages calculated from this pedigree are not population frequencies. |
| Genetics | Autosomal-recessive segregation of homozygous HOXA2 p.Gln186Lys (p.Q186K), affecting a highly conserved homeodomain residue. | Primary linkage and sequencing study (pqac-00000000, pqac-00000001). | Strong segregation evidence in the original pedigree; historical variant interpretation predates current ACMG/AMP criteria, so a contemporary laboratory should reassess classification and transcript-level HGVS nomenclature. |
| Mapping and functional support | Linked to chromosome 7p14.3–p15.3 with maximum multipoint LOD 4.17; p.Q186K was absent from 231 Iranian and 109 Belgian controls. Structural modeling predicted loss of a homeodomain–DNA phosphate hydrogen bond and altered DNA binding. | Primary human genetic and computational study (pqac-00000000). | Strong linkage and rarity evidence; protein effect was modeled computationally rather than demonstrated with a syndrome-specific cellular functional assay. |
| Core phenotype | Congenital bilateral Marx type II microtia, prelingual symmetric severe-to-profound mixed hearing impairment, and partial/incomplete cleft palate. | Original report summarized in authoritative review (pqac-00000000, pqac-00000005). | High within the pedigree; penetrance and expressivity in unrelated families remain unknown. |
| Inner-ear involvement | Unilateral cochlear absence occurred in one affected individual, showing that inner-ear involvement is possible in addition to predominant external- and middle-ear disease. | Human clinical/imaging observation (pqac-00000000, pqac-00000005). | Moderate; single-patient observation and not a reliable frequency estimate. |
| Mechanism | Reduced HOXA2 homeobox transcription-factor function is inferred to impair second-pharyngeal-arch cranial-neural-crest identity and patterning, leading to malformed pinna and middle-ear skeletal structures; abnormal palate development provides a route to cleft palate. | Human variant modeling plus Hoxa2 mouse developmental studies (pqac-00000000, pqac-00000016, pqac-00000019). | Biologically compelling but partly inferred; the complete molecular chain has not been demonstrated in patient-derived cells or tissues. |
| Mouse-model evidence | Hoxa2-deficient mice lack pinnae, have transformed or duplicated middle-ear skeletal elements and a wide secondary-palate cleft, and die shortly after birth; ectopic expression experiments establish a dosage-sensitive role in pharyngeal-arch identity. | Knockout/ developmental evidence summarized in reviews and primary-model literature (pqac-00000005, pqac-00000016, pqac-00000017). | Strong developmental evidence, but null-mouse lethality and severity exceed the surviving human missense phenotype. |
| Diagnosis | Molecular confirmation should identify biallelic HOXA2 variants after detailed craniofacial examination and audiologic assessment; diagnostic ABR should be performed by 2–3 months, with air- and bone-conduction thresholds. Temporal-bone CT/MRI is selected according to age, anatomy, suspected inner-ear disease, and surgical planning. | HOXA2 family evidence plus general microtia/atresia expert guidance (pqac-00000008, pqac-00000010, pqac-00000012). | Genetic testing is syndrome-directed; audiologic and imaging pathways are extrapolated because no syndrome-specific diagnostic guideline exists. |
| Management | Phenotype-directed multidisciplinary care may include early amplification and speech/language intervention, bone-conduction hearing systems when appropriate, anatomy-dependent atresia/hearing surgery, cleft-palate repair and speech therapy, and coordinated auricular reconstruction. | General microtia/atresia consensus and integrated-care recommendations (pqac-00000008, pqac-00000009, pqac-00000014, pqac-00000015). | No HOXA2-specific outcome data; treatment must account for the mixed hearing loss and possible cochlear aplasia rather than assuming isolated conductive loss. |
| Epidemiology and natural history | Syndrome-specific prevalence, incidence, carrier frequency, sex ratio, life expectancy, and longitudinal progression are unknown. | Only one pedigree has established the recessive syndromic phenotype (pqac-00000000, pqac-00000001). | Very low epidemiologic certainty; general microtia prevalence or sex ratios must not be assigned to this syndrome. |
| Disease-modifying therapy and trials | No established pharmacologic, gene, RNA, or cell therapy and no syndrome-specific interventional trial were identified; current care treats hearing, palate, speech, and reconstructive consequences. | Available disease evidence and microtia management literature (pqac-00000002, pqac-00000008, pqac-00000009). | Search-dependent negative finding; broader ear-reconstruction or hearing-device studies are not evidence for correction of the HOXA2 developmental lesion. |
| 2024 development | A distant approximately 600-kb craniofacial global control region was shown to interact with anterior HOXA genes; deletion in mice produced highly penetrant skull defects and orofacial clefts resembling Hoxa2-null phenotypes, while human copy-number changes were associated with severe craniofacial abnormalities. | Human embryonic epigenomics, mouse deletion experiments, and human CNV cases (pqac-00000003, pqac-00000007). | Important HOXA regulatory insight, but not direct evidence that this control region causes the named p.Q186K recessive syndrome or changes current treatment. |


*Table: This table separates observations established in the single reported HOXA2-associated pedigree from mouse-mechanistic evidence and clinical guidance extrapolated from broader microtia, hearing-loss, and cleft-care literature.*